Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
pharmaphorum3d
After FDA no, Regeneron gets yes from EU on odronextamab
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...
Zacks.com on MSN6d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
Nasdaq24d
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
Regeneron recently announced that the primary ... The drug has been approved under the brand name Ordspono. However, the company’s efforts to get odronextamab approved in the United States ...
Business Insider24d
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
“Regeneron continues to diversify our commercial ... Odronextamab is approved in the European Union as Ordspono™ to treat R/R FL or DLBCL after two or more lines of systemic therapy, but ...
Taiwan News23d
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Odronextamab is approved in the European Union as Ordspono™ to treat R/R FL or DLBCL after two or more lines of systemic therapy, but the safety and efficacy of odronextamab has not been fully ...